Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.403, 2003-01, pp. : 3-5
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
First-line imatinib mesylate worth it in CML
Inpharma, Vol. 1, Iss. 1378, 2003-01 ,pp. :
Access to resources
Recommend
Imatinib mesylate: best first-line pharmacotherapy for CML
Inpharma, Vol. 1, Iss. 1379, 2003-01 ,pp. :
IRIS: imatinib mesylate superior in first-line treatment of CML
Inpharma, Vol. 1, Iss. 1349, 2002-01 ,pp. :
Imatinib mesylate promising for CML
Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. :
Surpassing the success of imatinib mesylate in CML
Inpharma, Vol. 1, Iss. 1385, 2003-01 ,pp. :